Neal Meropol, Trincipal investigator of its Targeted Agent and Profiling Utilization Registry (TAPUR) Study, shared a post by American Society of Clinical Oncology (ASCO), adding:
“I am honored to take on the TAPUR Principal Investigator mantle. Thank you to American Society of Clinical Oncology (ASCO) leadership for giving me the opportunity to build upon the decade-long vision and foundation established by Dr. Rich Schilsky. TAPUR is a clinical trial platform designed explicitly with a cancer patient focus, to provide expanded treatment options while growing the evidence base for genomically-based therapeutics. Looking forward to working with ASCO staff, scientific volunteers, TAPUR clinical sites, and collaborators as we forge ahead.”
Quoting American Society of Clinical Oncology (ASCO)‘s post:
“We are proud to announce that Neal Meropol MD, has been named the new Principal Investigator of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study.
Dr. Meropol is a nationally recognized leader in precision oncology and brings a wealth of experience from both academic and real-world data settings. He will succeed Dr. Richard L. Schilsky, who will transition into the role of Founding Principal Investigator after a decade of incredible leadership.
Since 2016, the TAPUR Study has:
- Enrolled over 3,000 patients with advanced cancer.
- Been referenced in more than 800 scientific publications.
- Expanded access to targeted therapies based on genomic profiles rather than tumor type.
Please join us in welcoming Dr. Meropol as he leads TAPUR into its next phase of innovation!
Read the full announcement.”